Teva Proposes $40 Billion to Acquire Mylan
Teva announces that it would pay up to $40 billion in cash and stock to acquire Mylan.
Teva announced a proposal on April 21, 2015 to acquire Mylan for $40 billion, or $82 per share, in cash and stocks. According to a press release, the combined company would focus on complex technologies, more durable and sustainable products, and enhanced capabilities in specialty drug development and commercialization.
“We have long respected Mylan’s business, and we are confident that Mylan’s Board of Directors and stockholders will agree that our proposal represents a significantly more attractive alternative for Mylan and its stockholders than Mylan’s proposed acquisition of Perrigo,” said Erez Vigodman, president and CEO of Teva, in a press release.
This proposal comes a mere two weeks after Mylan proposed $29 billion to acquire Perrigo. The deal could have been a defensive move by Mylan, because Teva was already interested in acquiring Mylan, according to the New York Times. The Times continues by mentioning that Mylan’s executive chairman, Robert J. Coury, was quoted as saying earlier in the month that Mylan is committed to the Perrigo deal and is uninterested in an acquisition by Teva.
Source: Teva
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
